Clinical trial data and efficacy analysis of ixazomib (Enleri)

Ixazomib (Ixazomib) is an oral proteasome inhibitor mainly used to treat relapsed or refractory multiple myeloma (RRMM). Its mechanism of action is by inhibiting 26S proteasome activity, blocking the protein degradation pathway, leading to tumor cell apoptosis, thereby exerting anti-tumor effects. Compared with intravenously administered bortezomib, the oral dosage form of Ixazomib provides patients with a more convenient way of taking the drug, while showing comparable efficacy and good tolerability in clinical trials.

InIII phase clinical trial TOURMALINE-MM1 Among them, Ixazomib combined with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone) has shown significant efficacy in patients with relapsed or refractory multiple myeloma. The results of the study showed that the median progression-free survival (PFS) was 20.6 months, while the control group was only 14.7 months, indicating that the Ixazomib combination regimen can significantly delay disease progression. In addition, the overall response rate (ORR) reached 78%, and some patients achieved deep molecular response, indicating its positive role in improving patient prognosis.

In terms of safety, Ixazomib’s side effects are generally controllable. Common adverse events include gastrointestinal reactions (such as nausea, diarrhea), hematological abnormalities (such as thrombocytopenia, leukopenia) and fatigue, but most are grade 1-2 and can be managed through dose adjustment or symptomatic treatment. Clinical data show that Ixazomiboral administration has certain advantages over intravenous injection, which can reduce infusion-related adverse reactions while improving patient compliance and quality of life.

Overall, Ixazomib demonstrated reliable efficacy and a manageable safety profile in the treatment of relapsed or refractory multiple myeloma. Its oral dosage form facilitates long-term maintenance treatment, and the combination of lenalidomide and dexamethasone can significantly extend progression-free survival and improve the overall prognosis of patients. Based on clinical trial data, Ixazomib has become an important targeted treatment option for patients with relapsed myeloma, providing strong support for improving patient survival rate and quality of life.

Reference materials:https://www.drugs.com/